UY37064A - Método de purificación - Google Patents
Método de purificaciónInfo
- Publication number
- UY37064A UY37064A UY0001037064A UY37064A UY37064A UY 37064 A UY37064 A UY 37064A UY 0001037064 A UY0001037064 A UY 0001037064A UY 37064 A UY37064 A UY 37064A UY 37064 A UY37064 A UY 37064A
- Authority
- UY
- Uruguay
- Prior art keywords
- separation material
- solution
- product
- mixture
- purification method
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/04—Processes using organic exchangers
- B01J39/05—Processes using organic exchangers in the strongly acidic form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/16—Organic material
- B01J39/17—Organic material containing also inorganic materials, e.g. inert material coated with an ion-exchange resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
- A61N2005/1021—Radioactive fluid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención proporciona un método para la purificación de 227Th a partir de una mezcla que comprende 227Th y 223Ra, donde dicho método comprende: i) preparar una primera solución que comprende una mezcla de iones de 227Th y 223Ra disuelta en un primer buffer acuoso; ii) cargar dicha primera solución sobre un material de separación, tal como una resina de intercambio de cationes fuerte; iii) eluir 227Th del material de separación por lo cual se genera una segunda solución que comprende 227Th; iv) Opcionalmente enjuagar dicho material de separación mediante la utilización de un primer medio de lavado acuoso; La invención proporciona además un método para formar un producto radiofarmacéutico que comprende complejar 227Th purificado, el producto farmacéutico y su uso en el tratamiento de la enfermedad tal como el cáncer y un kit para la generación de dicho producto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1600161.2A GB201600161D0 (en) | 2016-01-05 | 2016-01-05 | Isotope purification method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37064A true UY37064A (es) | 2017-07-31 |
Family
ID=55406722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037064A UY37064A (es) | 2016-01-05 | 2017-01-05 | Método de purificación |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10729794B2 (es) |
| EP (1) | EP3400084A1 (es) |
| JP (1) | JP2019509327A (es) |
| CN (1) | CN108601992A (es) |
| AR (1) | AR107297A1 (es) |
| CA (1) | CA3010196A1 (es) |
| GB (1) | GB201600161D0 (es) |
| TW (1) | TW201726179A (es) |
| UY (1) | UY37064A (es) |
| WO (1) | WO2017118593A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2753033C1 (ru) * | 2020-06-09 | 2021-08-11 | Акционерное Общество "Производственное Объединение "Электрохимический завод" (АО "ПО ЭХЗ") | Способ разделения изотопов лантаноидов и тория с использованием метода газовых центрифуг |
| NO346827B1 (en) * | 2021-07-09 | 2023-01-23 | Node Pharma As | MOF for radiotherapy |
| CN114807636B (zh) * | 2021-12-31 | 2023-10-20 | 中国工程物理研究院核物理与化学研究所 | 一种无载体177Lu和161Tb的GMP生产方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
| EA201100177A1 (ru) * | 2005-06-17 | 2011-06-30 | Элан Фарма Интернэшнл Лимитед | СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201216764D0 (en) * | 2012-09-20 | 2012-10-31 | Dupont Nutrition Biosci Aps | Separation and recovery of xylose |
| GB201310028D0 (en) * | 2013-06-05 | 2013-07-17 | Algeta Asa | Pharmaceutical preparation |
-
2016
- 2016-01-05 GB GBGB1600161.2A patent/GB201600161D0/en not_active Ceased
- 2016-12-29 JP JP2018553304A patent/JP2019509327A/ja active Pending
- 2016-12-29 CN CN201680078261.2A patent/CN108601992A/zh active Pending
- 2016-12-29 CA CA3010196A patent/CA3010196A1/en active Pending
- 2016-12-29 US US16/067,675 patent/US10729794B2/en not_active Expired - Fee Related
- 2016-12-29 WO PCT/EP2016/082842 patent/WO2017118593A1/en unknown
- 2016-12-29 EP EP16822701.5A patent/EP3400084A1/en not_active Withdrawn
-
2017
- 2017-01-04 TW TW106100137A patent/TW201726179A/zh unknown
- 2017-01-05 UY UY0001037064A patent/UY37064A/es not_active Application Discontinuation
- 2017-01-05 AR ARP170100021A patent/AR107297A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3400084A1 (en) | 2018-11-14 |
| CN108601992A (zh) | 2018-09-28 |
| GB201600161D0 (en) | 2016-02-17 |
| US20190001005A1 (en) | 2019-01-03 |
| CA3010196A1 (en) | 2017-07-13 |
| WO2017118593A1 (en) | 2017-07-13 |
| JP2019509327A (ja) | 2019-04-04 |
| US10729794B2 (en) | 2020-08-04 |
| AR107297A1 (es) | 2018-04-18 |
| TW201726179A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37927A (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
| CO7111298A2 (es) | Composiciones de tratamiento de agua y métodos de uso | |
| ECSP12012160A (es) | Compuesto heterociclico | |
| UY33480A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento. | |
| MY197626A (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| NI201800071A (es) | Compuestos de isoindol | |
| AR112103A1 (es) | Compuestos para el tratamiento de tnbc | |
| UY37064A (es) | Método de purificación | |
| CR20160483A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| GB2545615A (en) | Cationic surfactants for scale inhibitor squeeze applications | |
| GT201700194A (es) | Formulación de combinación de tesofensina y betabloqueante | |
| MX2019005349A (es) | Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos. | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| AR058361A1 (es) | Composiciones lifolizadas de un compuesto de triazolopirimidina | |
| PE20170430A1 (es) | Arilhidrazidas que contienen una fraccion de 2-piridona como agentes antibacterianos selectivos | |
| CL2015000957A1 (es) | Métodos para reducir la formación de encrustante | |
| CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
| PH12015500399A1 (en) | Azaindolines | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| UY37065A (es) | Método de purificación | |
| CU20180110A7 (es) | Una composición que comprende pic para el tratamiento del cáncer | |
| AR107299A1 (es) | Método para la preparación de isótopos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20230601 |